ELV
ACHAT TOTAL: 3 725 titres (~1 364 517,25 $ US) VENTE TOTALE: 151 titres (~60 667,27 $ US)
- Insiders
- PERU RAMIRO G, BOUDREAUX GAIL, Dixon Robert L JR
- Total bought
- $1,364,517
- Total sold
- $60,667
- Last activity
- 2026-07-17
- Last synced
-
2026-07-29 15:28:58
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-07-29
ELV presents a compelling near-term event-driven setup — a Q2 earnings beat, raised 2026 EPS guidance, and high-conviction insider buying (~$1.36M by CEO and Chairman) drive a strong catalyst score of 85 with 0.85…
The first sentence of the analysis written for ELV on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 25.6% | 27.9% | 27.4% | 25.5% | 26.0% | |
| Ebit Margin | 4.1% | 5.1% | 5.1% | 5.4% | 6.3% | |
| Ebitda Margin | 4.9% | 5.9% | 6.1% | 6.5% | 7.2% | |
| Operating Profit Margin | 4.1% | 5.0% | 5.1% | 5.4% | 6.5% | |
| Pretax Profit Margin | 3.4% | 4.5% | 4.5% | 4.9% | 5.7% | |
| Continuous Operations Profit Margin | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | |
| Net Profit Margin | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | |
| Bottom Line Profit Margin | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | |
| Current Ratio | 1.239 | 1.099 | 0.971 | 1.026 | 0.939 | |
| Quick Ratio | 1.239 | 1.099 | 0.971 | 1.026 | 0.939 | |
| Solvency Ratio | 0.093 | 0.098 | 0.111 | 0.114 | 0.121 | |
| Cash Ratio | 0.476 | 0.427 | 0.334 | 0.396 | 0.314 | |
| Price To Earnings Ratio | 13.922 | 14.293 | 18.580 | 20.886 | 18.358 | |
| Price To Earnings Growth Ratio | -5.704 | 8.436 | 5.565 | -7.643 | 0.477 | |
| Forward Price To Earnings Growth Ratio | -5.704 | 8.436 | 5.565 | -7.643 | 0.477 | |
| Price To Book Ratio | 1.772 | 2.079 | 2.796 | 3.397 | 3.134 | |
| Price To Sales Ratio | 0.390 | 0.486 | 0.641 | 0.786 | 0.815 | |
| Price To Free Cash Flow Ratio | 24.497 | 18.872 | 16.246 | 16.988 | 15.530 | |
| Price To Operating Cash Flow Ratio | 18.124 | 14.791 | 13.634 | 14.658 | 13.512 | |
| Debt To Assets Ratio | 0.274 | 0.280 | 0.245 | 0.251 | 0.255 | |
| Debt To Equity Ratio | 0.757 | 0.792 | 0.678 | 0.712 | 0.690 | |
| Debt To Capital Ratio | 0.431 | 0.442 | 0.404 | 0.416 | 0.408 | |
| Long Term Debt To Capital Ratio | 0.417 | 0.420 | 0.378 | 0.389 | 0.379 | |
| Financial Leverage Ratio | 2.769 | 2.829 | 2.771 | 2.835 | 2.703 | |
| Working Capital Turnover Ratio | 59.520 | 260.590 | -3,984.651 | -659.347 | 371.686 | |
| Operating Cash Flow Ratio | 0.215 | 0.299 | 0.412 | 0.450 | 0.539 | |
| Operating Cash Flow Sales Ratio | 0.022 | 0.033 | 0.047 | 0.054 | 0.060 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.740 | 0.784 | 0.839 | 0.863 | 0.870 | |
| Debt Service Coverage Ratio | 3.095 | 2.550 | 2.857 | 3.008 | 2.922 | |
| Interest Coverage Ratio | 5.786 | 7.500 | 8.490 | 9.931 | 11.211 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.109 | 2.680 | 3.955 | 4.316 | 4.167 | |
| Operating Cash Flow Coverage Ratio | 0.129 | 0.178 | 0.302 | 0.326 | 0.336 | |
| Capital Expenditure Coverage Ratio | 3.844 | 4.624 | 6.220 | 7.291 | 7.695 | |
| Dividend Paid And Capex Coverage Ratio | 1.622 | 2.101 | 2.996 | 3.528 | 3.817 | |
| Dividend Payout Ratio | 0.270 | 0.252 | 0.233 | 0.209 | 0.181 | |
| Enterprise Value Multiple | 10.509 | 10.524 | 12.396 | 13.976 | 13.269 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 25.6% | ▼-2.3% | ▼-0.9% |
| Ebit Margin | 4.1% | ▼-1.1% | ▼-1.1% |
| Ebitda Margin | 4.9% | ▼-1.1% | ▼-1.3% |
| Operating Profit Margin | 4.1% | ▼-0.9% | ▼-1.1% |
| Pretax Profit Margin | 3.4% | ▼-1.1% | ▼-1.2% |
| Continuous Operations Profit Margin | 2.8% | ▼-0.5% | ▼-0.7% |
| Net Profit Margin | 2.8% | ▼-0.5% | ▼-0.7% |
| Bottom Line Profit Margin | 2.8% | ▼-0.5% | ▼-0.7% |
| Current Ratio | 1.239 | ▲0.140 | ▲0.184 |
| Quick Ratio | 1.239 | ▲0.140 | ▲0.184 |
| Solvency Ratio | 0.093 | ▼-0.005 | ▼-0.014 |
| Cash Ratio | 0.476 | ▲0.049 | ▲0.086 |
| Price To Earnings Ratio | 13.922 | ▼-0.371 | ▼-3.286 |
| Price To Earnings Growth Ratio | -5.704 | ▼-14.140 | ▼-5.930 |
| Forward Price To Earnings Growth Ratio | -5.704 | ▼-14.140 | ▼-5.930 |
| Price To Book Ratio | 1.772 | ▼-0.307 | ▼-0.864 |
| Price To Sales Ratio | 0.391 | ▼-0.095 | ▼-0.233 |
| Price To Free Cash Flow Ratio | 24.497 | ▲5.625 | ▲6.070 |
| Price To Operating Cash Flow Ratio | 18.124 | ▲3.333 | ▲3.180 |
| Debt To Assets Ratio | 0.274 | ▼-0.006 | ▲0.013 |
| Debt To Equity Ratio | 0.757 | ▼-0.034 | ▲0.032 |
| Debt To Capital Ratio | 0.431 | ▼-0.011 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.416 | ▼-0.003 | ▲0.020 |
| Financial Leverage Ratio | 2.769 | ▼-0.061 | ▼-0.013 |
| Working Capital Turnover Ratio | 59.520 | ▼-201.069 | ▲849.961 |
| Operating Cash Flow Ratio | 0.215 | ▼-0.084 | ▼-0.168 |
| Operating Cash Flow Sales Ratio | 0.021 | ▼-0.011 | ▼-0.021 |
| Free Cash Flow Operating Cash Flow Ratio | 0.740 | ▼-0.044 | ▼-0.079 |
| Debt Service Coverage Ratio | 3.095 | ▲0.544 | ▲0.208 |
| Interest Coverage Ratio | 5.786 | ▼-1.714 | ▼-2.798 |
| Short Term Operating Cash Flow Coverage Ratio | 3.109 | ▲0.428 | ▼-0.537 |
| Operating Cash Flow Coverage Ratio | 0.129 | ▼-0.049 | ▼-0.125 |
| Capital Expenditure Coverage Ratio | 3.844 | ▼-0.780 | ▼-2.091 |
| Dividend Paid And Capex Coverage Ratio | 1.622 | ▼-0.479 | ▼-1.191 |
| Dividend Payout Ratio | 0.270 | ▲0.018 | ▲0.041 |
| Enterprise Value Multiple | 10.509 | ▼-0.015 | ▼-1.626 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $77.75B | $85.90B | $109.91B | $123.11B | $113.01B | |
| Enterprise value | $101.50B | $110.32B | $130.03B | $141.52B | $133.02B | |
| EV / Sales | 0.51x | 0.62x | 0.76x | 0.90x | 0.96x | |
| EV / Op. cash flow | 23.66x | 18.99x | 16.13x | 16.85x | 15.90x | |
| EV / Free cash flow | 31.98x | 24.23x | 19.22x | 19.53x | 18.28x | |
| EV / EBITDA | 10.51x | 10.52x | 12.40x | 13.98x | 13.27x | |
| Net debt / EBITDA | 2.46x | 2.33x | 1.92x | 1.82x | 2.00x | |
| Current ratio | 1.24x | 1.10x | 0.97x | 1.03x | 0.94x | |
| Income quality | 0.76x | 0.97x | 1.35x | 1.40x | 1.37x | |
| Graham number | $337 | $320 | $312 | $289 | $289 | |
| Graham net-net | -$255 | -$246 | -$230 | -$209 | -$202 | |
| Tax burden | 84.4% | 75.7% | 77.6% | 77.6% | 77.0% | |
| Interest burden | 82.7% | 87.0% | 88.2% | 89.9% | 90.9% | |
| Working capital | $4.77B | $1.92B | -$565.0M | $479.0M | -$954.0M | |
| Invested capital | $49.44B | $47.51B | $39.97B | $40.10B | $38.44B | |
| Return on assets | 4.7% | 5.1% | 5.5% | 5.7% | 6.3% | |
| Operating ROA | 6.8% | 7.9% | 8.3% | 8.4% | 9.6% | |
| Return on tangible assets | 6.9% | 7.8% | 8.2% | 8.7% | 9.7% | |
| Return on equity | 12.9% | 14.5% | 15.2% | 16.3% | 16.9% | |
| Return on invested capital | 6.6% | 6.7% | 7.4% | 7.6% | 8.2% | |
| Return on capital employed | 8.0% | 9.1% | 9.8% | 10.0% | 10.9% | |
| Earnings yield | 7.3% | 7.0% | 5.4% | 4.8% | 5.4% | |
| Free cash flow yield | 4.1% | 5.3% | 6.2% | 5.9% | 6.4% | |
| Capex / Op. cash flow | 26.0% | 21.6% | 16.1% | 13.7% | 13.0% | |
| Capex / Depreciation | 72.2% | 90.2% | 74.3% | 68.8% | 83.5% | |
| Capex / Sales | 0.6% | 0.7% | 0.8% | 0.7% | 0.8% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | |
| Intangibles / Total assets | 32.5% | 34.5% | 32.7% | 33.8% | 35.8% | |
| Days sales outstanding | 28d | 27d | 27d | 27d | 26d | |
| Days payables outstanding | 42d | 45d | 47d | 49d | 48d | |
| Operating cycle | 28d | 27d | 27d | 27d | 26d | |
| Cash conversion cycle | -14d | -18d | -21d | -21d | -23d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-9.5%EV / Sales ▼-18.3%EV / EBITDA ▼-0.1%EV / Op. cash flow ▲+4.665Earnings yield ▲+0.003Graham number ▲+16.923
Profitability
Return on equity ▼-0.016Return on assets ▼-0.005Return on invested capital ▼-0.001Return on capital employed ▼-0.011Operating ROA ▼-0.011Income quality ▼-0.215Tax burden ▲+0.087
Efficiency
Days sales outstanding ▲+0.976Days payables outstanding ▼-2.984Operating cycle ▲+0.976Cash conversion cycle ▲+3.959Capex / Sales ▼-0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.140Net debt / EBITDA ▲+0.129Working capital ▲+2847000000.000Invested capital ▲+1932000000.000Intangibles / Total assets ▼-0.020
Change over 5 years
Valuation
Market cap ▼-31.2%EV / Sales ▼-46.9%EV / EBITDA ▼-20.8%EV / Op. cash flow ▲+7.755Earnings yield ▲+0.019Graham number ▲+48.445
Profitability
Return on equity ▼-0.040Return on assets ▼-0.016Return on invested capital ▼-0.015Return on capital employed ▼-0.029Operating ROA ▼-0.028Income quality ▼-0.614Tax burden ▲+0.074
Efficiency
Days sales outstanding ▲+2.412Days payables outstanding ▼-6.000Operating cycle ▲+2.412Cash conversion cycle ▲+8.412Capex / Sales ▼-0.002R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.300Net debt / EBITDA ▲+0.462Working capital ▲+5723000000.000Invested capital ▲+11008000000.000Intangibles / Total assets ▼-0.032
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-13 | Lisa McClain | Sale | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-10 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-24 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Sale | $15,001 - $50,000 |
| 2025-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-11 | Dan Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-10 | Jared Moskowitz | Sale | $1,001 - $15,000 |
| 2025-03-10 | Jared Moskowitz | Sale | $1,001 - $15,000 |
| 2025-03-10 | Jared Moskowitz | Sale | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-01-13 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-01-13 | Rob Bresnahan | Sale | $1,001 - $15,000 |
| 2025-01-09 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2024-11-19 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2024-11-08 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2024-09-11 | William R. Keating | Sale | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-07-05 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-07-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-04-10 | Dan Newhouse | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Michael McCaul | Exchange | $100,001 - $250,000 |
| 2024-03-25 | Michael McCaul | Sale | $100,001 - $250,000 |
| 2024-03-25 | Michael McCaul | Sale | $100,001 - $250,000 |
| 2024-02-20 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-13 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-02-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-02-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John Curtis | Sale | $1,001 - $15,000 |
| 2023-11-16 | John James | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-13 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-10-13 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-29 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-09-29 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Michael McCaul | Purchase | $100,001 - $250,000 |
| 2023-09-15 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-05 | Rick Larsen | Sale (Full) | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-10 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-05-10 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-04-26 | John Curtis | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-03-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-06 | Rick Larsen | Purchase | $1,001 - $15,000 |
| 2023-01-03 | Robert J. Wittman | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-20 | John Curtis | Sale (Full) | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-30 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2022-11-30 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2022-07-01 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2022-07-01 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2022-06-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-26 | Michael McCaul | Sale | $100,001 - $250,000 |
| 2022-05-26 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2022-05-20 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-05-06 | Michael McCaul | Sale | $100,001 - $250,000 |
| 2022-05-06 | Michael McCaul | Sale | $100,001 - $250,000 |
| 2022-01-28 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2021-12-15 | Michael McCaul | Sale | $15,001 - $50,000 |
Recent news
- 2026-07-21 Artisan Value Fund Q2 2026 Portfolio Update US equities advanced during Q2, supported by another quarter of better-than-expected corporate earnings and continued enthusiasm for companies benefiting from artificial intelligence-related investment. Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Our top five contributors to return in Q2 were Texas Instruments, Lam Research, NXP Semiconductors, Elevance Health and Alphabet.
- 2026-07-20 Elevance Health Chairman Ramiro Peru Buys $336,000 of Shares. What Does This Mean for Investors Right Now? The purchase of 1,000 shares at $366.05 per share represents a total capital commitment of $366,050. This transaction increased the director's total direct equity position by 10% relative to his pre-trade holdings.
- 2026-07-18 Elevance Health Q2 Earnings Call Highlights Elevance Health (NYSE: ELV) raised its 2026 adjusted earnings outlook after second-quarter results came in ahead of management's expectations, citing favorable benefit expense performance, disciplined cost management and improving execution across several major business lines. President and CEO Gail Boudreaux said the company now expects 2026 adjusted diluted earnings per share of at least $27. Chief
- 2026-07-17 Elevance Health CEO Boudreaux Buys $1 Million in Shares. What Does This Mean For its 2026 Outlook? The CEO executed an open-market purchase of 2,725 shares, representing a capital commitment of ~$1.0 million. The transaction increased the insider's total equity holdings by 2% of the previously held position.
- 2026-07-16 Big Hospital Systems Are Dropping Medicare Advantage Plans Mid-Contract. Patients Find Out by Letter Your Medicare Advantage plan stays active on paper, but the hospital you have used for decades can quietly vanish from your network before your next appointment, and the protections meant to help you come with conditions most patients never see coming.
- 2026-07-16 These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings Elevance Health Inc. (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.
- 2026-07-15 Elevance Health, Inc. (ELV) Q2 2026 Earnings Call Transcript Elevance Health, Inc. (ELV) Q2 2026 Earnings Call Transcript
- 2026-07-15 ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product Revenues Elevance Health beats Q2 EPS and revenue estimates, raises 2026 adjusted EPS outlook despite lower earnings, softer membership and higher expenses.
- 2026-07-15 Dow Jones Stays Calm While Memory Chips Give Investors Whiplash (Again) Inflation data gave investors hope on Wednesday morning. Semiconductor stocks took it away by lunchtime.
- 2026-07-15 Elevance Health Q2 Earnings Call Highlights Elevance Health NYSE: ELV raised its 2026 adjusted earnings outlook after second-quarter results came in ahead of management's expectations, citing favorable benefit expense performance, disciplined cost management and improving execution across several major business lines.